Literature DB >> 16166328

Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses.

Christophe Dercamp1, Karine Chemin, Christophe Caux, Giorgio Trinchieri, Alain P Vicari.   

Abstract

Lack of antitumor immunity is often related to impaired CD8 T-cell responses that could result from a poor priming capacity by tumor-infiltrating dendritic cells (TIDC) and/or further inhibition by regulatory T cells (T(reg)). Interleukin-10 (IL-10) has been implicated in the inhibition of TIDC as well as in the generation and functions of T(reg). Here, we address some of the respective and possibly overlapping roles of IL-10 and CD25+ T(reg) in CD8 antitumor immunity. Whereas tumor antigen-specific CD8 T cells proliferated in vivo in the presence of IL-10 or T(reg), optimal effector functions were observed in mice lacking both IL-10 and T(reg). Indeed, tumors grown in normal but not in IL-10-deficient or CD25-depleted mice induced tumor antigen-specific CD8 suppressor T cells. Suppression involved transforming growth factor-beta. Similarly, both IL-10 and T(reg) were responsible for impaired CD8 T cell priming by TIDCs, but IL-12 production by TIDCs was prevented only by T(reg)-independent IL-10. Subsequently, IL-10 defect and T(reg) depletion were required to achieve optimal induction of CD8 T-cell effectors by TIDC following CpG activation. Our results point out major redundant and nonredundant roles for IL-10 and T(reg) in the inhibition of TIDC-mediated generation of antitumor CD8 T-cell response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166328     DOI: 10.1158/0008-5472.CAN-05-1319

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

2.  Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance.

Authors:  Xi Zhu; Lin-Lin Ma; Tian Ye
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 3.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

4.  Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

Authors:  Maryam Ahmadi; Christine J Bryson; Edward A Cloake; Katie Welch; Vasco Filipe; Stefan Romeijn; Andrea Hawe; Wim Jiskoot; Matthew P Baker; Mark H Fogg
Journal:  Pharm Res       Date:  2015-04       Impact factor: 4.200

5.  The roles of IL-12 and IL-23 in CD8+ T cell-mediated immunity against Listeria monocytogenes: Insights from a DC vaccination model.

Authors:  Curtis J Henry; Jason M Grayson; Kristina L Brzoza-Lewis; Latoya M Mitchell; Marlena M Westcott; Anne S Cook; Elizabeth M Hiltbold
Journal:  Cell Immunol       Date:  2010-04-24       Impact factor: 4.868

6.  IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4+ T cells and promoting CTL persistence in a murine model of plasmacytoma.

Authors:  Lixin Wang; Jin-Qing Liu; Fatemeh Talebian; Zhenzhen Liu; Li Yu; Xue-Feng Bai
Journal:  Oncoimmunology       Date:  2015-05-13       Impact factor: 8.110

Review 7.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer.

Authors:  Sergei I Grivennikov; Michael Karin
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

8.  Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo.

Authors:  Maryam Ahmadi; David C Emery; David J Morgan
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

9.  Changes of CD4(+) CD25 (+) regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACE.

Authors:  Bin Xiong; Gansheng Feng; Shihua Luo; Huimin Liang; Lingyun Qiu; Chuansheng Zheng; Xi Liu; Guofeng Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-12-24

10.  PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.

Authors:  Wenshi Wang; Roy Lau; Daohai Yu; Weiwei Zhu; Alan Korman; Jeffrey Weber
Journal:  Int Immunol       Date:  2009-08-03       Impact factor: 4.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.